

May 15, 2018

Press Release

Nobelpharma Co., Ltd.

### **Private placement of shares to MEDIPAL HOLDINGS CORPORATION**

Nobelpharma Co., Ltd. (Head Office: Tokyo; President and CEO: Jin Shiomura) has concluded a private placement of shares to MEDIPAL HOLDINGS CORPORATION (hereinafter MEDIPAL, Head office: Chuo-ku, Tokyo; President and CEO: Shuichi Watanabe).

The private placement increased MEDIPAL's holdings in Nobelpharma from 7.12% to 20% of the outstanding shares, making Nobelpharma a MEDIPAL affiliated company that will be accounted for by the equity method.

Nobelpharma has been building a cooperative business and financial relationship with MEDIPAL since 2012. Last year, MEDIPAL joined Nobelpharma in a collaborative effort for sales of Nobelzin® upon approval of additional indication for hypozincemia. Nobelzin® is Nobelpharma first major product distributed through its own sales channel, and the strong tie-up with MEDIPAL achieved excellent results for the initial year of sales.

Nobelzin® is anticipated by the medical community to be effective in improving a variety of symptoms caused by low zin and fulfilling unmet needs. A market-creating product, Nobelzin® is a strategic product for Nobelpharma that also fits well with MEDIPAL's corporate strategy. This year, both companies aim to further promote Nobelzin® towards wider use, and, as Nobelpharma launches more products, intend to continue to enhance marketing and sales collaboration.

The private placement had the added benefit of improving Nobelpharma's balance sheet while furthering the business ties with MEDIPAL.

**【Contact】**

Nobelpharma Co., Ltd.

Kozo Hayase, Head of Administrative Affairs & Corporate Planning

Tel: 03-5651-1160